Products for Research Use Only

(Rac) -Apremilast

CAT: 0804-HY-I0635-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-I0635-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(Rac) -Apremilast ((Rac) -CC-10004) is the racemic mixture of Apremilast. (Rac) -Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis[1][2].
CAS Number
253168-86-4
Product Name Alternative
(Rac) -CC-10004
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rac-apremilast.html
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(NC1=CC=CC(C(N2C(C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O
Molecular Formula
C22H24N2O7S
Molecular Weight
460.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88 (1) :29-39. |[2]Man H W, et al. Discovery of (S) -N-{2-[1- (3-ethoxy-4-methoxyphenyl) -2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. Journal of medicinal chemistry, 2009, 52 (6) : 1522-1524.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE4